Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes

2018

ANTICANCER RESEARCH

Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes

01 Pubblicazione su rivista

Valeriani Maurizio, Bonfili Pierluigi, Reverberi Chiara, Marinelli Luca, Ferella Letizia, Minniti Giuseppe, DE Sanctis Vitaliana, Osti Mattia Falchetto, Bonome Paolo, Tronnolone Lidia, Varrassi Emilia, Gravina Giovanni Luca, Franzese Pietro, Tombolini Vincenzo, DI Staso Mario

DOI: 10.21873/anticanres.12400

ISSN: 0250-7005

Abstract
BACKGROUND/AIM:

To evaluate outcomes in patients with low-risk prostate cancer treated with hypofractionated radiotherapy (HyRT).
PATIENTS AND METHODS:

Between April 2004 and December 2015, 175 patients with low-risk prostate cancer were treated with HyRT 60 Gy in 20 fractions with or without image guidance and reduction of margin from clinical target volume to planning target volume.
RESULTS:

The median follow-up was 66 months. The 8-year overall survival for the whole patient cohort was 88.9%. The 8-year biochemical no evidence of disease was higher in patients treated with image-guided HyRT (98.8% vs. 88%, p=0.023). During treatment, patients treated with image-guided HyRT presented a lower rate of grade 1-2 gastrointestinal toxicity (25.3% vs. 42.2%, p=0.001). At the last follow-up, the grade 1 Gastro-intestinal toxicity rate was 4.0% and the grade 1-2 genito-urinary toxicity rate was 25.1%.
CONCLUSION:

Our study demonstrated the efficacy of the schedule used with a low rate of acute and late toxicities. Therefore, reduction of margins with image-guided HyRT is safe.

Aged 80 and over Dose Hypofractionation Follow-Up Studies Gastrointestinal Diseases Hypofractionation image-guided radiotherapy Kaplan-Meier Estimate low-risk prostate cancer Prostatic Neoplasms radiotherapy image-guided Risk Factors time factors Treatment Outcome